Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Accrued product revenue deductions by Year
Accrued product revenue deductions (rebates, chargebacks, discounts & returns, $M) ($M)
Vertex Pharmaceuticals Accrued product revenue deductions: $1,814M in FY2025, up 12.1% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Accrued Expenses Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued product revenue deductions (rebates, chargebacks, discounts & returns, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,814 | +12.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,619 | -5.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,716 | +31.9% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 1,301 | +53.5% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 847 | +8.4% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 782 | +21.9% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 641 | +16.6% | Form 10-K (filed 2021-02-11) ↗ |
| FY2018 | Dec 31, 2018 | 550 | +358.7% | Form 10-K (filed 2020-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 120 | +38.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 86.5 | +83.3% | Form 10-K (filed 2018-02-15) ↗ |
| FY2015 | Dec 31, 2015 | 47.2 | – | Form 10-K (filed 2017-02-23) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Accrued product revenue deductions ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/accrued-product-rev
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.